Morin Frick
About Morin Frick
Morin Frick is a Senior Scientist at Erasca, Inc. in South San Francisco, California, with over a decade of experience in process development and manufacturing in the pharmaceutical industry.
Work at Erasca
Morin Frick has been employed at Erasca, Inc. as a Senior Scientist since 2022. The role is based in South San Francisco, California. In this position, Frick contributes to the development of innovative therapies, leveraging extensive experience in process development and manufacturing.
Previous Experience in Pharmaceutical Industry
Frick has over a decade of experience in the pharmaceutical industry, including roles at Gilead Sciences, Global Blood Therapeutics, and Array BioPharma. At Gilead Sciences, Frick served as a Senior Research Associate II in Process Development from 2015 to 2019. Prior to that, Frick worked as a Process Chemist at Array BioPharma from 2014 to 2015 and held positions at Cedarburg Hauser Pharmaceuticals and University of Colorado Anschutz Medical Campus.
Education and Expertise
Morin Frick holds a Master of Science in Organic Chemistry from the University of Colorado at Boulder, achieved between 2007 and 2010. Frick also obtained a Bachelor of Science in Chemistry from the University of West Georgia from 2003 to 2007 and an Associate degree in Liberal Arts from Redlands Community College from 2001 to 2003. This educational background supports Frick's expertise in process development and regulatory compliance.
Leadership and Project Management
Frick has demonstrated leadership in various roles, including managing a cross-functional API team for development and technology transfer. This experience includes overseeing operations related to contract manufacturing organizations (CMOs) and ensuring successful process validation and commercial manufacturing. Frick's ability to manage teams across process chemistry, analytical chemistry, and quality assurance reflects strong project management skills.
Regulatory Compliance Experience
Frick has been involved in quality checking of drug substance sections for regulatory filings such as Investigational New Drug (IND), New Drug Application (NDA), and Marketing Authorization Application (MAA). This involvement indicates a solid understanding of regulatory compliance and industry standards, including Good Manufacturing Practice (GMP) principles and International Council for Harmonisation (ICH) guidelines.